X4 PHARMACEUTICALS INC (XFOR)

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

First U.S. commercial sales of XOLREMDI™ (mavorixafor) following April 2024 FDA approval Positive interim data from Phase 2 trial of mavorixafor in...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

Commit To Buy X4 Pharmaceuticals At $0.50, Earn 20% Using Options

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia...

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday!

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor) ...

XFOR Stock Earnings: X4 Pharmaceuticals Misses EPS for Q1 2024

XFOR stock results show that X4 Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

Commit To Buy X4 Pharmaceuticals At $1, Earn 48.2% Annualized Using Options

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023

XFOR stock results show that X4 Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.

XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips X4 Pharmaceuticals (NASDAQ:XFOR) just reported results for the fourth quarter o...

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30,...

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the...

Commit To Buy X4 Pharmaceuticals At $0.50, Earn 30% Using Options

B. Riley cuts X4 to neutral, cites longer-term mavorixafor data (NASDAQ:XFOR)

B. Riley has downgraded X4 Pharmaceuticals (XFOR) to neutral, citing disappointing data for mavorixafor in the treatment of chronic neutropenia. Read more here.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!